034317
Clone Type
PolyclonalHost
RabbitSource
HumanIsotype
IgGGrade
Affinity PurifiedApplications
E IHC WBCrossreactivity
HuAccession #
NP_758965.1; NP_066274.1;Gene ID
30848Gene #
CTAG2Shipping Temp
Blue IceStorage Temp
-20°CRabbit Anti-CTAG2, ID (CTAG2, ESO2, LAGE1, Cancer/testis antigen 2, Autoimmunogenic cancer/testis antigen NY-ESO-2, Cancer/testis antigen 6.2, L antigen family member 1)
CTAG2, ESO2, LAGE1, Cancer/testis antigen 2, Autoimmunogenic cancer/testis antigen NY-ESO-2, Cancer/testis antigen 6.2, L antigen family member 1
This gene encodes an autoimmunogenic tumor antigen that belongs to the ESO/LAGE family of cancer-testis antigens. This protein is expressed in a wide array of cancers including melanoma, breast cancer, bladder cancer and prostate cancer. This protein is also expressed in normal testis tissue. An alternative open reading frame product of this gene has been described in PMID 10399963. This alternate protein, termed CAMEL, is a tumor antigen that is recognized by melanoma-specific cytotoxic T-lymphocytes. Alternate splicing results in multiple transcript variants. [provided by RefSeq].
Applications
Suitable for use in Western Blot, Immunohistochemistry and ELISA. Other applications have not been tested.
Recommended Dilution
Western Blot: 1:1000 Immunohistochemistry (FFPE): 1:10-1:50 Optimal dilutions to be determined by researcher.
Storage and Stability
May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Aliquots are stable for 12 months after receipt. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
Immunogen
KLH-conjugated synthetic peptide mapping to a fragment of residues within amino acids 122-149 in the central region of human CTAG2.
Form
Supplied as a liquid in PBS, pH 7.2, 0.09% sodium azide.
Purity
Purified by Protein A and peptide affinity chromatography.
Specificity
Recognizes human CTAG2.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
References
1. Wang, X.Y., et al. Oncol. Rep. 21(3):713-719(2009) 2. Shao, Y., et al. J. Cancer Res. Clin. Oncol. 134(4):495-502(2008) 3. Andrade, V.C., et al. Cancer Immun. 8, 2 (2008) : 4. Kan, T., et al. Oncology 70(1):25-33(2006) 5. Scanlan, M.J., et al. Immunol. Rev. 188, 22-32 (2002) :USBio References
No references available